Gemilukast NEW
| Price | $289 | $496 | $962 |
| Package | 5mg | 10mg | 25mg |
| Supply Ability: | 10g |
| Update Time: | 2026-04-27 |
Product Details
| Product Name: Gemilukast | CAS No.: 1232861-58-3 |
| Purity: 99.92% | Supply Ability: 10g |
| Release date: 2026/04/27 |
Product Introduction
Bioactivity
| Name | Gemilukast |
| Description | Gemilukast (ONO-6950) is an orally active and potent dual inhibitor of cysteinyl leukotriene 1 and 2 receptors (CysLT1 and CysLT2), inhibits LTC 4-induced bronchoconstriction, and is inhibitory to human CysLT1 and CysLT2, and may be used in the treatment of asthma. |
| In vitro | Gemilukast is a potent dual antagonist for cysteinyl leukotriene 1 and 2 receptors (CysLT1 and CysLT2), and it is orally active. It exhibits IC50 values of 1.7 nM and 25 nM for human CysLT1 and CysLT2, respectively[2]. In comparison, both Gemilukast (ONO-6950) and montelukast inhibit the human CysLT1 receptor-mediated calcium response, with IC50 values of 1.7 nM and 0.46 nM, respectively[1]. |
| In vivo | Orally administered Gemilukast, at doses ranging from 0.03 to 10 mg/kg, demonstrates a dose-dependent attenuation of LTC4-induced bronchoconstriction, reaching almost complete inhibition at 3 mg/kg. Notably, Gemilukast's inhibitory effect on LTC4-induced bronchoconstriction is significantly stronger than that observed with montelukast at doses equal to or greater than 1 mg/kg.Furthermore, Gemilukast (at doses from 0.03 to 1 mg/kg, p.o.) dose-dependently attenuates LTD4-induced airway vascular hyperpermeability, achieving complete inhibition at 0.3 mg/kg. In the context of OVA-induced bronchoconstriction, Gemilukast at doses ranging from 0.1 to 3 mg/kg, p.o., exhibits a dose-dependent inhibitory effect. Particularly, the inhibitory effect of Gemilukast at 3 mg/kg surpasses that of montelukast alone and is comparable to the combination therapy involving montelukast and BayCysLT2RA[2]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 100 mg/mL (166.2 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 4 mg/mL (6.65 mM), Sonication is recommended. |
| Keywords | ONO6950 | ONO 6950 | Gemilukast | CysLTR | CysLT2 | CysLT1 |
| Inhibitors Related | Moxilubant HCl | Montelukast sodium | LTB4-IN-1 | L 674573 | Olsalazine disodium | Pirodomast | Pranlukast | Desloratadine | CGP 35949 | ABT-080 | Darbufelone mesylate | Ticolubant |
| Related Compound Libraries | Bioactive Compound Library | ReFRAME Related Library | Drug Repurposing Compound Library | Inhibitor Library | Orally Active Compound Library | Immunology/Inflammation Compound Library | Clinical Compound Library | Bioactive Compounds Library Max | Fluorochemical Library | GPCR Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $289.00 |
VIP4Y
|
TargetMol Chemicals Inc.
|
2026-04-27 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY